Qingdao Haier BiomedicalLtd's long-term financial performance appears promising with a satisfactory ROE and exceptional net income growth rate, even though it needs more efficient use of its profits.
With such significant downgrades from analysts, uncertainty around Qingdao Haier Biomedical Co.,Ltd's future prospects has been escalated. The company's slower projected growth, compared to the industry average, may point to potential business headwinds.
海爾生物股票討論區
$ST易購(002024.SZ)$
$阿里巴巴(BABA.US)$
$阿里巴巴-SW(09988.HK)$
$海爾生物(688139.SH)$
$小米集團-W(01810.HK)$
$ST易購(002024.SZ)$
$阿里巴巴-SW(09988.HK)$
$阿里巴巴(BABA.US)$
$小米集團-W(01810.HK)$
$美的集團(000333.SZ)$
$海爾生物(688139.SH)$
$ST易購(002024.SZ)$
$阿里巴巴-SW(09988.HK)$
$阿里巴巴(BABA.US)$
$小米集團-W(01810.HK)$
$海爾生物(688139.SH)$
$美的集團(000333.SZ)$
暫無評論